ERBB2 and breast carcinoma: Together, our data revealed key roles for the MED1/Jab1 axis in HER2-driven mammary tumorigenesis and its potential usage as a therapeutic target for the treatment of HER2 and ER double-positive luminal B subtypes of breast cancer.